MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients

被引:35
作者
Phang, Beng Hooi [1 ]
Linn, Yeh Ching [2 ]
Li, Huihua [3 ]
Sabapathy, Kanaga [1 ,4 ]
机构
[1] Natl Canc Ctr, Mol Carcinogenesis Lab, Div Cellular & Mol Res, Humphrey Oei Inst Canc Res, Singapore 169610, Singapore
[2] Singapore Gen Hosp, Dept Haematol, Singapore 169608, Singapore
[3] Natl Canc Ctr, Div Clin Trails & Epidemiol Sci, Humphrey Oei Inst Canc Res, Singapore 169610, Singapore
[4] Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore
基金
英国医学研究理事会;
关键词
leukaemia; MDM2; SNP; p53; codon; 72; survival;
D O I
10.1016/j.ejca.2008.02.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although mutations in p53 are rare in leukaemia, MDM2, the negative regulator of p53, is often overexpressed. Recently, a single nucleotide polymorphism (SNP) in the MDM2 promoter - within the oestrogen-receptor-binding region - resulting in either a G or T allele was shown to affect its transcription, with elevated MDM2 being produced when it is a G allele. Expectedly, SNP309G females were found to be at a higher risk of accelerated onset of cancers. We have therefore analysed, in a pilot study, whether the status of MDM2 SNP309 and p53 codon-72 polymorphism, which was also shown to affect cancer predisposition, would affect cancer risk, onset age, overall survival and response to therapy in Chinese leukaemia patients. p53 SNP was not associated with any of the parameters. However, in contrast to expectations, the MDM2 SNP309G allele was associated with reduced risk of leukaemia. No other association was found between SNP309 and other parameters in both males and females. Thus, the data highlights ethnic differences in the effects of this SNP on cancer risk. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:760 / 766
页数:7
相关论文
共 38 条
[1]   IS P53 POLYMORPHISM MAINTAINED BY NATURAL-SELECTION [J].
BECKMAN, G ;
BIRGANDER, R ;
SJALANDER, A ;
SAHA, N ;
HOLMBERG, PA ;
KIVELA, A ;
BECKMAN, L .
HUMAN HEREDITY, 1994, 44 (05) :266-270
[2]  
Bergamaschi G, 2004, HAEMATOLOGICA, V89, P868
[3]   Association of breast cancer outcome with status of p53 and MDM2 SNP309 [J].
Boersma, Brenda J. ;
Howe, Tiffany M. ;
Goodman, Julie E. ;
Yfantis, Harry G. ;
Lee, Dong H. ;
Chanock, Stephen J. ;
Ambs, Stefan .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (13) :911-919
[4]   A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans [J].
Bond, G. L. ;
Levine, A. J. .
ONCOGENE, 2007, 26 (09) :1317-1323
[5]   MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner [J].
Bond, Gareth L. ;
Hirshfield, Kim M. ;
Kirchhoff, Tomas ;
Alexe, Gabriella ;
Bond, Elisabeth E. ;
Robins, Harlan ;
Bartel, Frank ;
Taubert, Helge ;
Wuerl, Peter ;
Hait, William ;
Toppmeyer, Deborah ;
Offit, Kenneth ;
Levine, Arnold J. .
CANCER RESEARCH, 2006, 66 (10) :5104-5110
[6]   A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].
Bond, GL ;
Hu, WW ;
Bond, EE ;
Robins, H ;
Lutzker, SG ;
Arva, NC ;
Bargonetti, J ;
Bartel, F ;
Taubert, H ;
Wuerl, P ;
Onel, K ;
Yip, L ;
Hwang, SJ ;
Strong, LC ;
Lozano, G ;
Levine, AJ .
CELL, 2004, 119 (05) :591-602
[7]   No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer [J].
Campbell, Ian G. ;
Eccles, Diana M. ;
Choong, David Y. H. .
CANCER LETTERS, 2006, 240 (02) :195-197
[8]  
CHENEY MD, 2007, CANCER BIOL THER, V8, P7
[9]   The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].
Dumont, P ;
Leu, JIJ ;
Della Pietra, AC ;
George, DL ;
Murphy, M .
NATURE GENETICS, 2003, 33 (03) :357-365
[10]  
Ganguli G, 2003, MOL CANCER RES, V1, P1027